Class Action Lawsuit Filed Against GRAIL, Inc. Over Alleged Securities Fraud
Berger Montague PC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) on behalf of investors who purchased the company's stock between May 13, 2025, and February 19, 2026. The firm alleges that GRAIL failed to disclose critical information about its NHS-Galleri trial, including concerns over whether it could meet a key endpoint related to cancer detection efficacy. The lawsuit claims the company withheld detailed data from investors for an extended period before finally disclosing in February 2026 that the primary endpoint had not been met. This revelation led to a significant drop in GRAIL's stock price, falling nearly 51% on the day of disclosure. Investors have until August 4, 2026, to seek leadership roles within the class action. GRAIL is known for its Galleri test, which screens for over 50 cancer types through a blood draw and has been central to its business strategy.
Tickers: $GRAL
Topics: GRAIL, Inc. lawsuit NHS-Galleri trial stock price drop